S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:SUPN

Supernus Pharmaceuticals Stock Forecast, Price & News

$25.14
+1.00 (+4.14 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.18
Now: $25.15
$25.37
50-Day Range
$24.15
MA: $29.28
$31.45
52-Week Range
$13.12
Now: $25.15
$31.99
Volume998,221 shs
Average Volume609,714 shs
Market Capitalization$1.32 billion
P/E Ratio10.43
Dividend YieldN/A
Beta1.38
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in neurology and psychiatry in the United States. The company offers Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and in children 6 to 17 years of age; and Trokendi XR, an extended release topiramate, which is used for the prophylaxis of migraine headache, as well as for the treatment of epilepsy. Its product candidates comprise SPN-812, a viloxazine hydrochloride, which has completed phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-809, a viloxazine hydrochloride, which is in phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine, which is in phase III clinical trial for the treatment of bipolar disorder; and SPN-817 that is in phase I clinical trial to treat severe pediatric epilepsy disorders. The company markets its products through pharmaceutical wholesalers and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a phase II clinical program for NV-5138 in treatment-resistant depression. Supernus Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Rockville, Maryland.
Supernus Pharmaceuticals logo

Headlines

3 Undervalued Biotechs Worth Adding to Your Watch List
February 27, 2021 |  finance.yahoo.com
Supernus to Present at Cowen Healthcare Conference
February 26, 2021 |  finance.yahoo.com
Supernus Pharmaceuticals: Q4 Earnings Insights
February 25, 2021 |  finance.yahoo.com
SUPN Mar 2021 30.000 put
January 5, 2021 |  uk.finance.yahoo.com
Sizing Up Supernus Pharmaceuticals
December 30, 2020 |  seekingalpha.com
Supernus Up on Report of Progress With ADHD Treatment
December 23, 2020 |  finance.yahoo.com
Why Supernus Pharmaceuticals Stock Is Rising Today
December 23, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:SUPN
CUSIP86845910
Phone301-838-2500
Employees464
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$392.76 million
Cash Flow$2.23 per share
Book Value$11.35 per share

Profitability

Net Income$113.06 million

Miscellaneous

Market Cap$1.32 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.62 out of 5 stars

Medical Sector

351st out of 1,972 stocks

Pharmaceutical Preparations Industry

165th out of 772 stocks

Analyst Opinion: 2.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$25.14
+1.00 (+4.14 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

Is Supernus Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Supernus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SUPN, but not buy additional shares or sell existing shares.
View analyst ratings for Supernus Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Supernus Pharmaceuticals?

Wall Street analysts have given Supernus Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Supernus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Supernus Pharmaceuticals
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted its earnings results on Thursday, February, 25th. The specialty pharmaceutical company reported $0.57 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.57. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 20.02% and a net margin of 27.09%.
View Supernus Pharmaceuticals' earnings history
.

How has Supernus Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SUPN shares have increased by 55.7% and is now trading at $25.1450.
View which stocks have been most impacted by COVID-19
.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals updated its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $550-580 million, compared to the consensus revenue estimate of $581.47 million.

What price target have analysts set for SUPN?

3 equities research analysts have issued 1-year target prices for Supernus Pharmaceuticals' stock. Their forecasts range from $24.00 to $35.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $27.67 in the next twelve months. This suggests a possible upside of 10.0% from the stock's current price.
View analysts' price targets for Supernus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the following people:
  • Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 60, Pay $1.49M)
  • Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 64, Pay $537.2k)
  • Ms. Tami T. Martin, Sr. VP of Regulatory Affairs (Age 66, Pay $450.28k)
  • Dr. Stefan K. F. Schwabe, Consultant (Age 69, Pay $584.04k)
  • Mr. James Patrick Kelly, Exec. VP & CFO (Age 55)
  • Dr. Todd Horich M.B.A., Ph.D., VP of Marketing
  • Mr. Taylor Raiford, VP of Sales
  • Dr. Bryan A. Roecklein, VP of Corp. Devel.
  • Mr. Frank Mottola, Sr. VP of Quality, GMP Operations & Information Technology (Age 49)
  • Dr. Jonathan Rubin, Sr. VP & Chief Medical Officer (Age 60)

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals CEO Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among Supernus Pharmaceuticals' employees.

Who are some of Supernus Pharmaceuticals' key competitors?

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (5.92%), Dimensional Fund Advisors LP (3.67%), Renaissance Technologies LLC (3.51%), GW&K Investment Management LLC (2.50%), Fuller & Thaler Asset Management Inc. (2.47%) and Aequim Alternative Investments LP (2.47%). Company insiders that own Supernus Pharmaceuticals stock include Frederick M Hudson, Gregory S Patrick, Jack A Khattar and Stefan KF Schwabe.
View institutional ownership trends for Supernus Pharmaceuticals
.

Which institutional investors are selling Supernus Pharmaceuticals stock?

SUPN stock was sold by a variety of institutional investors in the last quarter, including Burney Co., Armistice Capital LLC, Matarin Capital Management LLC, Price T Rowe Associates Inc. MD, Victory Capital Management Inc., Aristotle Capital Boston LLC, Glenmede Trust Co. NA, and Northern Trust Corp. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Frederick M Hudson, Gregory S Patrick, and Stefan KF Schwabe.
View insider buying and selling activity for Supernus Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Supernus Pharmaceuticals stock?

SUPN stock was acquired by a variety of institutional investors in the last quarter, including Aequim Alternative Investments LP, Stephens Investment Management Group LLC, Norges Bank, HealthInvest Partners AB, SummerHaven Investment Management LLC, Ashford Capital Management Inc., Fuller & Thaler Asset Management Inc., and GW&K Investment Management LLC.
View insider buying and selling activity for Supernus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $25.15.

How much money does Supernus Pharmaceuticals make?

Supernus Pharmaceuticals has a market capitalization of $1.32 billion and generates $392.76 million in revenue each year. The specialty pharmaceutical company earns $113.06 million in net income (profit) each year or $2.10 on an earnings per share basis.

How many employees does Supernus Pharmaceuticals have?

Supernus Pharmaceuticals employs 464 workers across the globe.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is www.supernus.com.

Where are Supernus Pharmaceuticals' headquarters?

Supernus Pharmaceuticals is headquartered at 1550 E GUDE DR, ROCKVILLE MD, 20850.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.